Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 8, 2006, Pages 2842-2844

  Malik, Muhammad ^a   Drlica, Karl ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; BAY Y3114; BMS 433368; CHLORAMPHENICOL; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); GATIFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; IN VITRO STUDY; LD 50; LETHALITY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION;

ANTITUBERCULAR AGENTS; AZA COMPOUNDS; CHLORAMPHENICOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROQUINOLONES; KINETICS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; MYCOBACTERIUM TUBERCULOSIS; PROTEIN SYNTHESIS INHIBITORS; QUINOLINES;

EID: 33746900110     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00250-06     Document Type: Article

References (18)

1. Alvirez-Freites, E., J. Carter, and M. Cynamon. 2002. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46:1022-1025.
2. Chen, C.-R., M. Malik, M. Snyder, and K. Drlica. 1996. DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage. J. Mol. Biol. 258:627-637.
3. Dong, Y., X. Zhao, B. Kreiswirth, and K. Drlica. 2000. Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 44:2581-2584.
4. Howard, B. M., R. J. Pinney, and J. T. Smith. 1993. 4-Quinolone bactericidal mechanisms. Arzneimittelforschung 43:1125-1129.
5. Jacobs, W. R., G. V. Kalpana, J. D. Cirillo, L. Pascopella, S. B. Snapper, R. A. Udani, W. Jones, R. G. Barletta, and B. R. Bloom. 1991. Genetic systems in mycobacteria. Methods Enzymol. 204:537-555.
6. Lewin, C., I. Morrissey, and J. Smith. 1991. The mode of action of quinolones: the paradox in activity of low and high concentrations and activity in the anaerobic environment. Eur. J. Clin. Microbiol. Infect. Dis. 10:240-248.
7. Lewin, C., and J. Smith. 1988. Bactericidal mechanisms of ofloxacin. J. Antimicrob. Chemother. 22(Suppl. C):1-8.
8. Lu, T., and K. Drlica. 2003. In vitro activity of C-8-methoxy fluoroquinolones against mycobacteria when combined with anti-tuberculosis agents. J. Antimicrob. Chemother. 52:1025-1028.
9. Malik, M., T. Lu, X. Zhao, A. Singh, C. Hattan, J. Domagala, R. Kerns, and K. Drlica. 2005. Quinolone lethality in the presence and absence of chloramphenicol: studies with Mycobacterium smegmatis. Antimicrob. Agents Chemother. 49:2008-2014.
10. Miyazaki, E., M. Miyazaki, J. Chen, R. Chaisson, and W. Bishai. 1999. Moxifloxacin (Bay 12-8039), a new 9-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob. Agents Chemother. 43:85-89.
11. Mogues, B. T., M. Goodrich, L. Ryan, R. LaCourse, and R. North. 2001. The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice. J. Exp. Med. 193:271-280.
12. Rodriguez, H., M. Ruiz, M. Lopez, and G. Royo. 2002. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin, and linezolid against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 20:464-467.
13. Wayne, L. G. 1994. Dormancy of Mycobacterium tuberculosis and latency of disease. Eur. J. Clin. Microbiol. Infect. Dis. 13:908-914.
14. Wayne, L. G., and L. G. Hayes. 1996. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect. Immun. 64:2062-2069.
15. Wolfson, J., and D. Hooper. 1989. Bacterial resistance to quinolones: mechanisms and clinical importance. Rev. Infect. Dis. 11(Suppl. 5):S960-S968.
16. Yoshimatsu, T., E. Nuermberger, S. Tyagi, R. Chaisson, W. Bishai, and J. Grosset. 2002. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob. Agents Chemother. 46:1875-1879.
17. Zhao, X., J.-Y. Wang, C. Xu, Y. Dong, J. Zhou, J. Domagala, and K. Drlica. 1998. Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones. Antimicrob. Agents Chemother. 42:956-958.
18. Zhao, X., C. Xu, J. Domagala, and K. Drlica. 1997. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc. Natl. Acad. Sci. USA 94:13991-13996.